461432-24-6

Basic information

• Product Name: (3R,4R,5R,6S)-2-(acetoxyMethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate
• Synonyms: (3R,4R,5R,6S)-2-(acetoxyMethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate;D-Glucopyranoside, Methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)Methyl]phenyl]-;Methyl 1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucopyranoside;(3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)-2-methoxytetrahydro-2H-pyran-3,4,5-triol;EOS-61485
• CAS NO: 461432-24-6
• Molecular Formula: C₂₂H₂₇ClO₇
• Molecular Weight: 577.01932
• Mol File: 461432-24-6.mol

Chemical Properties

• Boiling Point: 609.6±55.0 °C(Predicted)
• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 12.59±0.70(Predicted)
• CAS DataBase Reference: (3R,4R,5R,6S)-2-(acetoxyMethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate(CAS DataBase Reference)
• NIST Chemistry Reference: (3R,4R,5R,6S)-2-(acetoxyMethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate(461432-24-6)
• EPA Substance Registry System: (3R,4R,5R,6S)-2-(acetoxyMethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate(461432-24-6)

Safety Data

• Hazardous Substances Data: 461432-24-6(Hazardous Substances Data)

Upstream product

• 461432-23-5 4-bromo-1-chloro-2-[(4-ethoxyphenyl)methyl]benzene 
• 32469-28-6 (3R,4S,5R,6R)-3,4,5-tris((trimethylsilyl)oxy)-6-(((trimethylsilyl)oxy)methyl)tetrahydro-2H-pyran-2-one 
• 67-56-1 methanol 
• 960494-15-9 C₃₃H₅₇ClO₇Si₄ 
• 281652-58-2 2-chloro-5-iodobenzoylchloride 
• 103-73-1 Phenetole 
• 19094-56-5 2-chloro-5-iodobenzoic acid 
• 1103738-29-9 1-chloro-2-(4-ethoxybenzyl)-4-iodobenzene 
• 90-80-2 D-Glucono-1,5-lactone 
• 100227-29-0 5,6-di-O-isopropylidene-D-glucono-1,4-lactone 
• 21739-92-4 5-bromo-2-chlorobenzoic acid 
• 21900-52-7 5-bromo-2-chloro-benzoyl chloride 
• 75-75-2 methanesulfonic acid 
• 461432-22-4 (5-bromo-2-chlorophenyl)(4-ethyloxyphenyl)methanone 

Downstream Products

• 1118566-45-2 (1S)-1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol 
• 461432-26-8 dapagliflozin 
• 1204219-27-1 (2R,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-2-d-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol 
• 461432-25-7 (2R,3R,4R,5S,6S)-2-(acetoxymethyl)-6-(4-chloro-3-(4-ethoxybenzyl)phenyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate 

Relevant articles and documents

PREPARATION OF HIGHLY PURE AMORPHOUS DAPAGLIFLOZIN

A novel and improved process for the preparation of amorphous dapagliflozin is disclosed. The present invention further provides pharmaceutical compositions containing amorphous dapagliflozin, optionally in a combination with one or more other active substances and methods for making the same.

AMORPHOUS ERTUGLIFLOZIN AND PROCESS FOR ITS PREPARATION

An amorphous form of ertugliflozin and process for its preparation is described. A solid form of ertugliflozin and process for preparation thereof is also described.

Design, synthesis and biological evaluation of nitric oxide releasing derivatives of dapagliflozin as potential anti-diabetic and anti-thrombotic agents

The cardiovascular complications were highly prevalent in type 2 diabetes mellitus (T2DM), even at the early stage of T2DM or the state of intensive glycemic control. Therefore, there is an urgent need for the intervention of cardiovascular complications in T2DM. Herein, the new hybrids of NO donor and SGLT2 inhibitor were design to achieve dual effects of anti-hyperglycemic and anti-thrombosis. As expected, the preferred hybrid 2 exhibited moderate SGLT2 inhibitory effects and anti-platelet aggregation activities, and its anti-platelet effect mediated by NO was also confirmed in the presence of NO scavenger. Moreover, compound 2 revealed significantly hypoglycemic effects and excretion of urinary glucose during an oral glucose tolerance test in mice. Potent and multifunctional hybrid, such as compound 2, is expected as a potential candidate for the intervention of cardiovascular complications in T2DM.

Dicyclic derivative of glucoside as well as preparation method and application of dicyclic derivative

The invention relates to a dicyclic derivative of glucoside as well as a preparation method and the application of the dicyclic derivative. Specifically, the invention relates to a compound as shown in Formula I, a stereisomer or pharmaceutically acceptable salt or ester of the compound, a pharmaceutical composition of the compound, and application of the compound in preparation of drugs for treating diabetes or relevant diseases.

PREMIX OF DAPAGLIFLOZIN AND PROCESS FOR THE PREPARATION THEREOF

The present invention relates to a premix of dapagliflozin with lactose, processes for its preparation, and pharmaceutical composition thereof. The invention also relates to a process for the preparation of an amorphous dapagliflozin and crystalline dapagliflozin propanediol hydrate.

Method for purifying dapagliflozin

The invention discloses a method for purifying dapagliflozin. The method comprises the steps of carrying out coupled reaction on 4-bromo-1-chloro-2-2-(4-ethoxybenzyl)-benzene as shon in a formula I and 2,3,4,6- tetra-O-trimethylsilyl-D-glucolactone, and removing trimethylsilyl to obtain a compound as shown in a formula II; removing methoxyl from the compound as shown in the formula II to prepare a compound as shown in a formula III; protecting hydroxyl in the compound as shown in the formula III to obtain a compound as shown in a formula IV; and finally hydrolyzing the compound as shown in the formula IV to prepare the dapagliflozin. The method is simple in process, relatively mild in operation condition and available in raw materials, and a product with higher purity can be obtained at high yield, thereby reducing the production cost.

Method for synthesizing irregular glucitol

The invention relates to a method for synthesizing irregular glucitol (1S)-1,5-dehydration-1-[4-chlorine-3-[(4-ethyoxyl phenyl) methyl] phenyl]-D-glucitol. The reaction formula of the compound is as shown in the specification. The method is gentle in process reaction condition, simple and convenient to operate, applicable to industrial production and relatively high in total product yield, that is, the total product yield is 43-53%, and medicine-grade irregular glucitol 6 is easily prepared.

ISOLATED INTERMEDIATE OF DAPAGLIFLOZIN, PROCESS FOR THE PREPARATION OF ISOLATED INTERMEDIATE OF DAPAGLIFLOZIN, PROCESS FOR THE PREPARATION OF DAPAGLIFLOZIN

Aspects of the present invention relates to an isolated intermediate of Dapagliflozin (Formula III) and its preparation, process for the preparation of Dapagliflozin, process for the preparation of crystalline propane-1,2,3-triol solvate of dapagliflozin, process for the preparation of L-proline complex of Dapagliflozin, solid premix of dapagliflozin with the polymer selected from the group consisting of eudragit, syloid, MCC Avicel PH 102 (1:1) and MCC Avicel PH 102 (1:2).

PROCESS FOR PREPARATION OF DAPAGLIFLOZIN

The present invention relates to a process for the preparation of amorphous dapagliflozin. The present invention relates to 2,3-butanediol solvate of dapagliflozin and process for its preparation.

C - aryl glucoside SGLT2 inhibitor

The invention relates to the field of medicines related to diabetes mellitus and particularly relates to a 2-type sodium-glucose co-transporter (SGLT2) inhibitor with a multi-aryl glucoside structure and shown as the specification, a preparation method thereof, a medicine composition taking the compound as an active components and an application thereof in preparing medicines for resisting diabetes mellitus.